Gilead Sciences (GILD) Cash & Equivalents (2009 - 2026)

Gilead Sciences (GILD) has reported Cash & Equivalents for 18 consecutive years, with $7.6 billion the latest figure, recorded in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $7.6 billion, down 3.76% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.6 billion (down 3.76% YoY), and the FY2025 annual result was $7.6 billion, down 24.29% from the prior year.
• Cash & Equivalents was $7.6 billion for Q1 2026 at Gilead Sciences, up from $7.6 billion in the prior quarter.
• Over five years, Cash & Equivalents peaked at $10.0 billion in Q4 2024 and troughed at $2.8 billion in Q2 2024.
• Average Cash & Equivalents over 5 years is $5.9 billion, with a median of $5.4 billion recorded in 2022.
• Year-over-year, Cash & Equivalents sank 51.4% in 2024 and jumped 85.57% in 2025.
• Over 5 years, Cash & Equivalents stood at $5.4 billion in 2022, then rose by 12.44% to $6.1 billion in 2023, then soared by 64.19% to $10.0 billion in 2024, then dropped by 24.29% to $7.6 billion in 2025, then advanced by 0.85% to $7.6 billion in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $7.6 billion in Q1 2026, $7.6 billion in Q4 2025, and $7.3 billion in Q3 2025.